Introducing a therapy selection panel designed specifically for your early-stage NSCLC patients, brought to you by the market leader in Oncology Diagnostics for over 20 years.
Why Test EARLY?
Put your patients on a path towards better outcomes – right from the start of their cancer journey.
Current guidelines recommend:
- Perioperative biomarker testing for all patients with stage IB-IIIA/B NSCLC
- Considering both stage and known mutations/PD-L1 status when choosing
Personalized oncology intervention immediately after an early-stage diagnosis is possible – but it requires the full picture.
PD-L1 = programmed cell death ligand 1.
Personalized oncology intervention immediately after an early-stage diagnosis is possible – but it requires the full picture.
The Early-stage NSCLC Panel:
- Offers testing for actionable and informative biomarkers in early-stage NSCLC:
- Provides a quick and concise but comprehensive overview of actionable information aligned with the latest in emerging clinical evidence
- Assists in selecting the most appropriate targeted therapies for improved patient outcomes
ALK = anaplastic lymphoma kinase; EGFR = epidermal growth factor receptor; ROS1 = c-ros oncogene 1; PD-L1 = programmed cell death ligand 1.
* (TAT) Turnaround time is 7 days. Results are integrated into a final comprehensive report.
Resources
Easy ordering through NeoAccess - Streamlined, online ordering platform with built-in advanced clinical decision support to simplify biomarker testing
LEARN MORE
Includes NeoSeek - A platform that enables you to visualize all of your previous patient's NeoGenomics data and export them into a report
LEARN MORE
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients